Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hidradenitis suppurativa with and without draining tunnels: A real-world study characterizing differences in treatment and disease burden.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Dementia and Its Profound Impact on Family Members and Partners: A Large UK Cross-Sectional Study.

Alzheimer disease and associated disorders·2024
Same author

The Dermatology Life Quality Index (DLQI) used as the benchmark in validation of 101 quality-of-life instruments: A systematic review.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Measurement of the major ignored burden of multiple myeloma, pernicious anaemia and of other haematological conditions on partners and family members: A cross-sectional study.

European journal of haematology·2024
Same author

Responsiveness and minimal important change of the Family Reported Outcome Measure (FROM-16).

Journal of patient-reported outcomes·2024

Related Experiment Video

Updated: Jul 1, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Nicotine enemas for active Crohn's colitis: an open pilot study.

J R Ingram1, J Rhodes, B K Evans

  • 1Department of Gastroenterology, Cardiff and Vale NHS Trust, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK.

Gastroenterology Research and Practice
|September 17, 2008
PubMed
Summary

Nicotine enemas showed clinical benefit for most patients with active Crohn's colitis, reducing disease activity and inflammation markers. This treatment was well-tolerated and safe in this pilot study.

Related Experiment Videos

Last Updated: Jul 1, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Smoking negatively impacts Crohn's disease (CD), but non-nicotine factors may be responsible.
  • Transdermal nicotine shows benefits in ulcerative colitis (UC), suggesting potential for CD.

Purpose of the Study:

  • To evaluate the efficacy and safety of nicotine enemas for active Crohn's colitis.

Main Methods:

  • An open pilot study administered 6 mg nicotine enemas daily for 4 weeks to patients with active rectosigmoid CD.
  • Assessed Crohn's Disease Activity Index (CDAI), sigmoidoscopy, and inflammatory markers before and after treatment.

Main Results:

  • Mean CDAI decreased from 202 to 153, with improvement in 6/10 patients.
  • Bowel movement frequency reduced in 8 patients, and sigmoidoscopy grade improved in 7.
  • Mean C-reactive protein levels dropped from 22.0 to 12.3 mg/L; no adverse event withdrawals.

Conclusions:

  • Nicotine enemas demonstrated clinical benefit in the majority of patients with active Crohn's colitis.
  • The treatment was safe and well-tolerated in this patient cohort.